Navigation Links
Seattle Reproductive Medicine Study Investigates Newly Formulated Medications for Luteal Support in IVF
Date:1/14/2009

SEATTLE, Jan. 14 /PRNewswire/ -- Patients undergoing in vitro fertilization self-administer daily injections of progesterone from two to eight weeks after the egg retrieval procedure. The outcome of a new study of an investigational formulation of progesterone could replace these painful intramuscular injections of progesterone in oil with less painful subcutaneous injections.

Seattle Reproductive Medicine (SRM), along with eight other large fertility centers across the country, has been selected to participate in a study designed to compare the safety and effectiveness of an investigational aqueous formulation of progesterone that will be compared to a form of progesterone administered intra-vaginally.

"For years patients have complained about these injections. One shot may be tolerable, but many weeks of daily injections is a long time for this degree of discomfort," says Dr. Michael Soules, MD, SRM's managing partner. Dr. Soules is the principle investigator for the U.S. arm of this study. He adds, "Being a large practice affords us the opportunity to make these types of studies available to our patients. These studies help patients offset the cost of their treatment."

Progesterone supplementation is routinely given after egg recovery for two weeks or longer to assist embryo implantation and support of the uterine lining. Progesterone in oil injected intramuscularly is the usual means of administration. These self-administered injections can be quite painful. The drug being tested is a new formulation of an existing approved medication. If outcome, tolerability and safety are the same or better with the investigational formulation of progesterone then patients would no longer be subjected to these drugs.

Study participants must be in an IVF cycle and will receive study related medications valued near $300 at no cost and a $1500 payment for participation. Enrollment in the study is now open and patients interested in participating should contact Seattle Reproductive Medicine for more information.

About Seattle Reproductive Medicine

Seattle Reproductive Medicine is led by a nationally recognized team of seven physicians who offer comprehensive, state-of-the-art assistance for couples with infertility and women with reproductive endocrine problems. Drs. Soules and Klein have received several National Institutes of Health (NIH) research grants over the years and the Clinic's work in reproductive aging has received prominent media coverage in Seattle. Seattle Reproductive Medicine is a member of IntegraMed, an exclusive network of 140 physicians and scientists limited to the highest performing infertility practices. One of every five procedures in the United States is performed in an IntegraMed practice. For more information, visit http://www.SeattleFertility.com.


'/>"/>
SOURCE Seattle Reproductive Medicine
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. A Place for Mom COO Makes Seattles 40 Under 40 List
2. Seattle Surgeon Named 2007 Veterinarian of the Year
3. Math battling cancer, deciding lifes challenges lead list as INFORMS meet in Seattle
4. WELLESSE ALL DAY ENERGY(TM) - Sponsors of the UW Medical Center 2007 Seattle Marathon
5. MultiCare Joins Seattle Cancer Care Alliance Network
6. Seattle Cancer Care Alliance and Northwest Hospital Sign Letter of Intent to Develop Proton Therapy Center for Cancer Treatment
7. Upscale Seattle-Based Skincare Clinic Expands Into California With Unique Custom Tailored Skincare Approach
8. Seattle-Based Law Firm Williams Kastner Receives Significant Defense Verdict in Trade Secret Business Litigation Case
9. Seattle-Based Marsha Rivkin Center for Ovarian Cancer Research Appoints Nancy Sclater, Executive Director
10. Compressus Announces Seattle Radiologists Interoperability Implementation
11. Seattle Laces Up To Beat the Bridge and Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... New studies published today ... workers across 15 states. The outcomes examined in these studies include recovery of ... and satisfaction with medical care. , “The goal of the studies is to ...
(Date:5/25/2016)... ... May 25, 2016 , ... Cheryl Bowker of Bowker Insurance Group has ... McKenna Good Hands Legacy Award. McKenna ran one of Allstate’s most successful agencies for ... all those who knew him. The award named for him is not given every ...
(Date:5/25/2016)... ... May 25, 2016 , ... Casa Velas, an adults-only ... of precious stones to complement its new wellness suites . The two 1,350 ... feature a plethora of special services and insuite amenities, from a custom soap selection ...
(Date:5/25/2016)... PALM BEACH COUNTY, FLA (PRWEB) , ... May 25, 2016 , ... ... Florida the latest technology to help turn back the hands of time of female ... with female aging and childbirth. Women with symptoms such as leakage, laxity, itchiness ...
(Date:5/25/2016)... ... May 25, 2016 , ... First Choice Emergency Room , the largest ... Nguyen, as the Medical Director of its new DeSoto facility. , “We are ... DeSoto location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... NEW YORK , May 23, 2016 /PRNewswire/ ... Mass Spectrometry Market Size, Share, Development, Growth and ... Platform (Hybrid, Single and Other), by Application (Drug ... Others), by End Users (Pharmaceuticals, Life Science and ... Published by P&S Market Research, the global ...
(Date:5/23/2016)... DHABI , UAE, May 23, 2016 ... the importance of Precision Medicine and the role ...     The First International Conference ... under the distinguished patronage and presence of Sheikh Nahyan ... The conference focused in Precision Medicine, which helps provide personalized ...
(Date:5/22/2016)... , May 23, 2016 ... develop its anti-fibrotic and anti-inflammatory compound DS102 in ... as in non-alcoholic steatohepatitis (NASH) patients. ... significantly sequestered in lung tissue and has bronchodilatory, ... after oral administration. The Company will publish further ...
Breaking Medicine Technology: